Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | SPR | P35270 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390381 | 0.96 | JAK3 (0.43) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL23994976 | 0.92 | JAK3 (0.39) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL20965559 | 0.90 | JAK3 (0.41) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL2981422 | 0.82 | JAK3 (0.48) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL18389854 | 0.82 | JAK3 (0.50) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL26126544 | 0.81 | JAK3 (0.49) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL29584537 | 0.81 | JAK3 (0.47) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL18711284 | 0.80 | JAK3 (0.48) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL18390604 | 0.79 | JAK3 (0.47) | JAK3SPRNAMPTGRIN2BGRIN2C | |
| SCHEMBL18705170 | 0.78 | JAK3 (0.47) | JAK3SPRNAMPTGRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | JAK3 47/4885SPR 1785/4885NAMPT 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.